# Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

> **NCT00754052** · PHASE3 · TERMINATED · sponsor: **Eisai Inc.** · enrollment: 8 (actual)

## Conditions studied

- Down Syndrome
- Cognitive Dysfunction

## Interventions

- **DRUG:** Aricept (donepezil hydrochloride)
- **DRUG:** Aricept (donepezil hydrochloride)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00754052
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2008-11
- **Final completion:** 2008-12
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Sufficient evidence of efficacy not met. Discontinuation not based on any safety concerns.
- **Last updated:** 2018-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00754052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00754052, "Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00754052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*